id,inc,complex,inc_clean
NCT05143151,The ECOG score is 0-2 points;,0,The ECOG score is 0-2 points
NCT04714593,"The clinical laboratory test results of screening phase meet the following criteria: (7 days before the inspection without blood transfusion) Hb≥60 g/L (allowed to use recombinant human erythropoietin); PLT≥ 50 x 10 ^ 9 / L ; ALC≥0.3×10^9/L; ANC≥0.75×10^9/L (allowed to use granulocyte colony stimulating factor); AST≤3ULN,ALT≤3ULN,TBIL≤2ULN；Ccr≥30 mL/min/1.73 m2；",1,"The clinical laboratory test results of screening phase meet the following criteria: (7 days before the inspection without blood transfusion) Hb≥60 g/L (allowed to use recombinant human erythropoietin); PLT≥ 50 x 10 ^ 9 / L ; ALC≥0.3×10^9/L; ANC≥0.75×10^9/L (allowed to use granulocyte colony stimulating factor); AST≤3ULN,ALT≤3ULN,TBIL≤2ULN;Ccr≥30 mL/min/1.73 m2"
NCT02794961,Greater than four years of age,0,Greater than four years of age
NCT05627323,Confirmed MMP2+ tumor expression by IHC (≥20% moderate/high MMP2 score [2+ or 3+]).,0,Confirmed MMP2+ tumor expression by IHC (≥20% moderate/high MMP2 score [2+ or 3+]).
NCT05437341,"Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN.",1,"Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN."
NCT03815383,"Age 18-75 years old, male or female.",1,"Age 18-75 years old, male or female."
NCT05437328,"Patients with tumors received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent.",1,"Patients with tumors received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent."
NCT03277729,"Patients with waldenstrom macroglobulinemia (WM) without radiologic evidence of disease are eligible if they have measurable disease, as defined by serum monoclonal M-spike of >= 0.5 g/dL",1,"Patients with waldenstrom macroglobulinemia (WM) without radiologic evidence of disease are eligible if they have measurable disease, as defined by serum monoclonal M-spike of >= 0.5 g/dL"
NCT04697290,Double positive expression of CD19 / CD20 in B cells;,0,Double positive expression of CD19 / CD20 in B cells
NCT05618041,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT01683279,"CD19+ Leukemia with indication for HCT, but has contraindication",0,"CD19+ Leukemia with indication for HCT, but has contraindication"
NCT04715217,"The Clinical diagnosis of recurrent/refractory B cell lymphoma, after at least 2 courses of treatment, has not been achieved partial response, still in the continuous phase and progress, including the MRD positive, or recurrent intramedullary patients；",1,"The Clinical diagnosis of recurrent/refractory B cell lymphoma, after at least 2 courses of treatment, has not been achieved partial response, still in the continuous phase and progress, including the MRD positive, or recurrent intramedullary patients"
NCT05137275,"Hematologic system (no blood transfusion or hematopoietic stimulator treatment within 14 days)
 

 Absolute neutrophil count (ANC) ≥1.5×109/L
 Platelet (PLT) ≥75×109/L
 Hemoglobin (Hb) ≥85g/L
 Hepatic function
 Total bilirubin (TBIL) ≤1.5×ULN
 Alanine aminotransferase (ALT) ≤3×ULN;
 Patients with liver metastasis or liver cancer: ≤5×ULN
 Aspartate aminotransferase (AST) ≤3×ULN;
 Patients with liver metastasis or liver cancer: ≤5×ULN Renal function
 Creatinine (Cr) ≤1.5× ULN
 Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5× ULN) > -50ml/min/1.73m2 (Cockcroft-Gault formula) Coagulation function
 Activated partial thrombin time (APTT) ≤1.5×ULN
 International normalized ratio (INR) ≤1.5×ULN",1,Hematologic system (no blood transfusion or hematopoietic stimulator treatment within 14 days) Absolute neutrophil count (ANC) ≥1.5×109/L Platelet (PLT) ≥75×109/L Hemoglobin (Hb) ≥85g/L Hepatic function Total bilirubin (TBIL) ≤1.5×ULN Alanine aminotransferase (ALT) ≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN Aspartate aminotransferase (AST) ≤3×ULN; Patients with liver metastasis or liver cancer: ≤5×ULN Renal function Creatinine (Cr) ≤1.5× ULN Creatinine clearance (Ccr) (to be calculated only when Cr > 1.5× ULN) > -50ml/min/1.73m2 (Cockcroft-Gault formula) Coagulation function Activated partial thrombin time (APTT) ≤1.5×ULN International normalized ratio (INR) ≤1.5×ULN
NCT04317885,11. Expected survival ≥ 3months,0,Expected survival ≥ 3months
NCT02846584,Expected survival time of patients enrolled is over 3 months.,0,Expected survival time of patients enrolled is over 3 months.
NCT04601831,"All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",0,"All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately."
NCT02715362,"Persistent cancer after at least one prior standard of care chemotherapy, has no willing for surgery or cannot be suitable for surgery patients;",1,"Persistent cancer after at least one prior standard of care chemotherapy, has no willing for surgery or cannot be suitable for surgery patients"
NCT03881774,patients with refractory/relapsed B cell leukemia/lymphoma whose diseases relapse after autologous CAR-T cells or the preparation for autologous CAR-T cells fails,0,patients with refractory/relapsed B cell leukemia/lymphoma whose diseases relapse after autologous CAR-T cells or the preparation for autologous CAR-T cells fails
NCT05123209,Estimated survival ≥ 12 weeks;,0,Estimated survival ≥ 12 weeks
NCT02842138,ineligible for allogeneic transplantation or relapsed after transplantation.,1,ineligible for allogeneic transplantation or relapsed after transplantation.
NCT04464200,Adequate pulmonary function as assessed by ≥92% oxygen saturation on room air by pulse oximetry.,0,Adequate pulmonary function as assessed by ≥92% oxygen saturation on room air by pulse oximetry.
NCT03380039,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT04827745,Female subjects of childbearing potential must have a negative pregnancy test,0,Female subjects of childbearing potential must have a negative pregnancy test
NCT05577091,Age: 18 years to 70 years (including cut-off values).,0,Age: 18 years to 70 years (including cut-off values).
NCT05281809,Subjects must consent to anonymous reporting of data to the CIBMTR (Center for International Blood and Marrow Transplant Research).,0,Subjects must consent to anonymous reporting of data to the CIBMTR (Center for International Blood and Marrow Transplant Research).
NCT04303247,"Subjects must meet the following criteria for inclusion in the study： 1) Male or female subjects between the ages of 18 and 75（including critical values）； 2) Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) ：",1,"Subjects must meet the following criteria for inclusion in the study: 1) Male or female subjects between the ages of 18 and 75(including critical values); 2) Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) :"
NCT02937103,"Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.",1,"Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO."
NCT04008394,"Pathological and histological examination confirmed CD30+ lymphocyte malignancies, and patients currently have no effective treatment options, such as chemotherapy or recurrence after hematopoietic stem cell transplantation; or patients voluntarily choose Anti-CD30 CAR-T as rescue treatment.",1,"Pathological and histological examination confirmed CD30+ lymphocyte malignancies, and patients currently have no effective treatment options, such as chemotherapy or recurrence after hematopoietic stem cell transplantation; or patients voluntarily choose Anti-CD30 CAR-T as rescue treatment."
NCT03327285,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT05306080,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03720496,At least one measurable lesion per revised IWG Response Criteria;,0,At least one measurable lesion per revised IWG Response Criteria
NCT04792489,No clinical suspicion of central nervous system (CNS) lymphoma (not applicable to CNS cohort),0,No clinical suspicion of central nervous system (CNS) lymphoma (not applicable to CNS cohort)
NCT05022849,Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1,0,Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1
NCT05442580,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT05381181,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04085159,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03019055,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT03030001,"7. Adequate venous access for apheresis, and no other contraindications for leukapheresis ; Peripheral venous access ；no contraindication of lymphocyte separation.",1,"Adequate venous access for apheresis, and no other contraindications for leukapheresis ; Peripheral venous access ;no contraindication of lymphocyte separation."
NCT04089215,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05127135,"Ages Eligible for Study: 3 Years to 70 Years (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 3 Years to 70 Years (Child, Adult, Older Adult)"
NCT02247609,Life expectancy ≥3 months.,0,Life expectancy ≥3 months.
NCT04640909,Anticipated possibility to collect blood samples at the baseline and at 6- and 12-month timepoints;,0,Anticipated possibility to collect blood samples at the baseline and at 6- and 12-month timepoints
NCT04812691,Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of JWCAR029;,0,Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of JWCAR029
NCT05463640,The expression of ADGRE2 in AML blast is positive ;,0,The expression of ADGRE2 in AML blast is positive 
NCT03208556,life expectancy > 3months.,0,life expectancy > 3months.
NCT03790891,Aged <70 years;,0,Aged <70 years
NCT02735291,"All patients with acute non T lymphocytic leukemia after conventional treatment is invalid or recurrence of refractory, and by flow cytometry or pathological immunohistochemical examination, confirm the leukemia cells express can intervene molecular targets;",1,"All patients with acute non T lymphocytic leukemia after conventional treatment is invalid or recurrence of refractory, and by flow cytometry or pathological immunohistochemical examination, confirm the leukemia cells express can intervene molecular targets"
NCT04796688,"Having a measurable or evaluable lesion:
 A. Patients with lymphoma require a single lesion≥15mm or 2 or more lesions≥10mm.
 B. Patients with leukemia require persistent positive or positive relapse of bone marrow MRD.",1,Having a measurable or evaluable lesion: A. Patients with lymphoma require a single lesion≥15mm or 2 or more lesions≥10mm. B. Patients with leukemia require persistent positive or positive relapse of bone marrow MRD.
NCT03434769,Subjects must have relapsed or refractory non-Hodgkin lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.,1,Subjects must have relapsed or refractory non-Hodgkin lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.
NCT03179007,"Gender unlimited, age from 18 years to 80 years.",1,"Gender unlimited, age from 18 years to 80 years."
NCT01087294,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04268706,"<p>Eligibility is determined prior to blood collection . Patients must satisfy the following criteria to be enrolled in the study:</p><ol><ol>
 <li>Signed Informed Consent Form</li>
 <li>Male or female patients who are 12 - 75 years of age</li>
 <li>Histologically confirmed classical Hodgkin Lymphoma</li>
 <li>
 <p>Relapsed or refractory cHL that has failed at least 3 prior lines of therapy, including:</p>
 <ul>
 <li>chemotherapy</li>
 <li>BV and/or</li>
 <li>PD-1 inhibitor Patients may have previously received an autologous and/or allogeneic stem cell transplant</li>
 </ul>
 </li>
 <li>CD30-positive tumor</li>
 <li>At least 1 measurable lesion according to The Lugano Classification</li>
 <li>
 <p>Laboratory parameters: Hematological, renal and hepatic functions, and coagulation parameters</p>
 <ul>
 <li>Hgb ≥ 8.0 g/dL</li>
 <li>Total bilirubin ≤ 1.5 × ULN</li>
 <li>AST and ALT ≤ 5 × the ULN</li>
 <li>CrCl &gt; 45 mL/min</li>
 <li>ANC &gt;1,000/µL</li>
 <li>Platelets &gt;75,000/µL</li>
 <li>PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN</li>
 </ul>
 </li>
 <li>ECOG PS of 0 to 1 or equivalent [either Karnofsky PS (for patients ≥ 16 year of age) or Lansky PS (for patients &lt; 16 years of age)]</li>
 <li>Anticipated life expectancy &gt; 12 weeks</li>
 </ol></ol>",1,"<p>Eligibility is determined prior to blood collection . Patients must satisfy the following criteria to be enrolled in the study:</p><ol><ol> <li>Signed Informed Consent Form</li> <li>Male or female patients who are 12 - 75 years of age</li> <li>Histologically confirmed classical Hodgkin Lymphoma</li> <li> <p>Relapsed or refractory cHL that has failed at least 3 prior lines of therapy, including:</p> <ul> <li>chemotherapy</li> <li>BV and/or</li> <li>PD-1 inhibitor Patients may have previously received an autologous and/or allogeneic stem cell transplant</li> </ul> </li> <li>CD30-positive tumor</li> <li>At least 1 measurable lesion according to The Lugano Classification</li> <li> <p>Laboratory parameters: Hematological, renal and hepatic functions, and coagulation parameters</p> <ul> <li>Hgb ≥ 8.0 g/dL</li> <li>Total bilirubin ≤ 1.5 × ULN</li> <li>AST and ALT ≤ 5 × the ULN</li> <li>CrCl > 45 mL/min</li> <li>ANC >1,000/μL</li> <li>Platelets >75,000/μL</li> <li>PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN</li> </ul> </li> <li>ECOG PS of 0 to 1 or equivalent [either Karnofsky PS (for patients ≥ 16 year of age) or Lansky PS (for patients < 16 years of age)]</li> <li>Anticipated life expectancy > 12 weeks</li> </ol></ol>"
NCT02893189,Confirmed diagnosis of CD19+ malignancy relapsing following allogeneic transplantation,0,Confirmed diagnosis of CD19+ malignancy relapsing following allogeneic transplantation
NCT05633615,STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must be registered within 28 days of the date of progression,0,STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants must be registered within 28 days of the date of progression
NCT05370547,Eastern Cooperative Oncology Group (ECOG) physical status is 0-3;,0,Eastern Cooperative Oncology Group (ECOG) physical status is 0-3
NCT03758417,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04270461,"Fail or unwilling to receive first-line treatment,",0,"Fail or unwilling to receive first-line treatment,"
NCT03380039,"Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.",1,"Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis."
NCT05477927,"Voluntarily participate in the research, understand and sign the informed consent;",0,"Voluntarily participate in the research, understand and sign the informed consent"
NCT03019055,Agree to practice birth control during the study.,0,Agree to practice birth control during the study.
NCT03103971,"<p>INCLUSION CRITERIA FOR LYMPHODEPLETING CHEMOTHERAPY AND huJCAR014 TREATMENT</p><ul><ul>
 <li>Successful collection of T cells for huJCAR014 manufacturing</li>
 <li>Detectable disease by imaging (for example PET +/- CT, magnetic resonance imaging [MRI]) and/or pathology evaluation</li>
 <li>Karnofsky performance status &gt;= 60%</li>
 <li>Assessed by the investigator to have adequate bone marrow function to receive lymphodepleting conditioning chemotherapy</li>
 <li>Serum creatinine =&lt; 1.5 x age-adjusted upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft and Gault) &gt; 30 mL/min/1.73 m^2</li>
 <li>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 5 x ULN and total bilirubin &lt; 2.0 mg/dL unless due to malignancy or Gilbert's syndrome in the opinion of the PI or designee</li>
 <li>Common Terminology Criteria for Adverse Events (CTCAE) grade =&lt; 1 dyspnea and oxygen saturation (SaO2) &gt;= 92% on room air</li>
 <li>Left ventricular ejection fraction (LVEF) &gt;= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy</li>
 <li>
 <p>Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must agree to both of the following:</p>
 <ul>
 <li>Use highly effective methods of contraception for at least 6 months after the last dose of huJCAR014, and</li>
 <li>Have a negative serum pregnancy test performed within 28 days before starting lymphodepleting chemotherapy</li>
 </ul>
 </li>
 <li>Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for at least 6 months after the last dose of huJCAR014</li>
 </ul></ul>",1,"<p>INCLUSION CRITERIA FOR LYMPHODEPLETING CHEMOTHERAPY AND huJCAR014 TREATMENT</p><ul><ul> <li>Successful collection of T cells for huJCAR014 manufacturing</li> <li>Detectable disease by imaging (for example PET +/- CT, magnetic resonance imaging [MRI]) and/or pathology evaluation</li> <li>Karnofsky performance status >= 60%</li> <li>Assessed by the investigator to have adequate bone marrow function to receive lymphodepleting conditioning chemotherapy</li> <li>Serum creatinine =< 1.5 x age-adjusted upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft and Gault) > 30 mL/min/1.73 m^2</li> <li>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN and total bilirubin < 2.0 mg/dL unless due to malignancy or Gilbert's syndrome in the opinion of the PI or designee</li> <li>Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1 dyspnea and oxygen saturation (SaO2) >= 92% on room air</li> <li>Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy</li> <li> <p>Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must agree to both of the following:</p> <ul> <li>Use highly effective methods of contraception for at least 6 months after the last dose of huJCAR014, and</li> <li>Have a negative serum pregnancy test performed within 28 days before starting lymphodepleting chemotherapy</li> </ul> </li> <li>Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for at least 6 months after the last dose of huJCAR014</li> </ul></ul>"
NCT05128786,"Capable of receiving treatment and follow-up, including treatment in the clinical center;",0,"Capable of receiving treatment and follow-up, including treatment in the clinical center"
NCT05105152,Subject and/or legally authorized representative has signed the Informed Consent Form for this study,0,Subject and/or legally authorized representative has signed the Informed Consent Form for this study
NCT03706326,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04377932,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT01454596,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT05143112,9) No contraindications to peripheral blood apheresis,0,No contraindications to peripheral blood apheresis
NCT05438368,"For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent.",0,"For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent."
NCT05634785,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05489991,Gender Based Eligibility: Yes,0,Gender Based Eligibility: Yes
NCT05020444,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03029338,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05518253,"The function of important organs is basically normal:
 

 Hematopoietic function: neutrophils>1.0×109/L, platelets>75×109/L, hemoglobin>80g/L;
 Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
 Renal function: serum creatinine≤2.0×ULN;
 Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN);
 Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN);
 Oxygen saturation > 92% in non-oxygen state.",1,"The function of important organs is basically normal: Hematopoietic function: neutrophils>1.0×109/L, platelets>75×109/L, hemoglobin>80g/L; Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram; Renal function: serum creatinine≤2.0×ULN; Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN); Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN); Oxygen saturation > 92% in non-oxygen state."
NCT05639972,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03937544,"Ages Eligible for Study: 13 Years to 65 Years (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 13 Years to 65 Years (Child, Adult, Older Adult)"
NCT04860817,Eastern cooperative oncology group (ECOG) performance status of 0 to 1,0,Eastern cooperative oncology group (ECOG) performance status of 0 to 1
NCT04186520,"<p>Phase 1: 3+3 COHORT ELEGIBILITY CRITERIA</p><ol><ol>
 <li>Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), Mantle Cell Lymphoma, and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell/histocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).</li>
 <li>
 <p>Patients must have active, measurable disease as defined and meet one of the following criteria.</p>
 <ol>
 <li>Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.</li>
 <li>Relapse post-autologous transplant</li>
 <li>Relapse post-allogeneic transplant</li>
 <li>Patients not previously treated with CAR-T cell therapy</li>
 </ol>
 </li>
 </ol></ol>",1,"<p>Phase 1: 3+3 COHORT ELEGIBILITY CRITERIA</p><ol><ol> <li>Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), Mantle Cell Lymphoma, and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell/histocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).</li> <li> <p>Patients must have active, measurable disease as defined and meet one of the following criteria.</p> <ol> <li>Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.</li> <li>Relapse post-autologous transplant</li> <li>Relapse post-allogeneic transplant</li> <li>Patients not previously treated with CAR-T cell therapy</li> </ol> </li> </ol></ol>"
NCT04727008,"Male or female, 18 to 75 years old.",1,"Male or female, 18 to 75 years old."
NCT03393936,Ongoing treatment using systemic steroid or steroid inhalants.,0,Ongoing treatment using systemic steroid or steroid inhalants.
NCT04093648,"Ages Eligible for Study: 1 Year and older (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 1 Year and older (Child, Adult, Older Adult)"
NCT03879382,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT03585764,Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.,1,Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.
NCT02846584,"Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)",1,"Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)"
NCT04093648,"Ages Eligible for Study: 1 Year and older   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 1 Year and older (Child, Adult, Older Adult)"
NCT03380039,Patients aged between 18 ~ 70 with relapsed or refractory multiple myeloma.,1,Patients aged between 18 ~ 70 with relapsed or refractory multiple myeloma.
NCT04265963,"No other illness may conflict with the protocol (e.g. autoimmune diseases, immune deficiency and organ transplantation；",0,"No other illness may conflict with the protocol (e.g. autoimmune diseases, immune deficiency and organ transplantation"
NCT02976857,Subject's left ventricular ejection fraction (LVEF) is ≥ 50% and no evidence of pericardial effusion as determined by an ECHO,1,Subject's left ventricular ejection fraction (LVEF) is ≥ 50% and no evidence of pericardial effusion as determined by an ECHO
NCT02723942,Karnofsky Performance Status(KPS)>=60；Expected survival time>=12 weeks.,1,Karnofsky Performance Status(KPS)>=60;Expected survival time>=12 weeks.
NCT03154775,At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor ≥ 1.5 cm),0,At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor ≥ 1.5 cm)
NCT02186860,Aspartate transaminase-alanine transaminase ratio < 3x normal,0,Aspartate transaminase-alanine transaminase ratio < 3x normal
NCT04976218,Previous treatment with anti-PD-1/PD-L1 antibodies are allowed.,0,Previous treatment with anti-PD-1/PD-L1 antibodies are allowed.
NCT05627323,"In-range baseline laboratory values for WBC (>2000/dL [or ANC ≥1000/mm^3]), platelets (≥75000/mm^3), total bilirubin (≤1.5xULN), AST (≤2.5xULN), ALT (≤2.5xULN), serum creatinine (≤1.5xmg/dL), and oxygen saturation (≥95% on room air)",1,"In-range baseline laboratory values for WBC (>2000/dL [or ANC ≥1000/mm^3]), platelets (≥75000/mm^3), total bilirubin (≤1.5xULN), AST (≤2.5xULN), ALT (≤2.5xULN), serum creatinine (≤1.5xmg/dL), and oxygen saturation (≥95% on room air)"
NCT03706326,"Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.",1,"Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration."
NCT05445765,The expected survival period is greater than 12 weeks;,0,The expected survival period is greater than 12 weeks
NCT03879382,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT03232619,ALL patients not eligible for allogeneic SCT or relapse after allogeneic SCT.,0,ALL patients not eligible for allogeneic SCT or relapse after allogeneic SCT.
NCT03585764,Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.,0,Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.
NCT05451212,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04289220,"9. Peripheral superficial venous blood flow is smooth, which can meet the needs of intravenous drip;",0,"Peripheral superficial venous blood flow is smooth, which can meet the needs of intravenous drip"
NCT04696432,"Age 18-70 years (include 18 and 70), male or female;",1,"Age 18-70 years (include 18 and 70), male or female"
NCT04735471,"Prior treatment must include at least 2 prior regimens, including anti CD20 antibody therapies. Prior Treatment with CD19 CAR T may be considered.",0,"Prior treatment must include at least 2 prior regimens, including anti CD20 antibody therapies. Prior Treatment with CD19 CAR T may be considered."
NCT02846584,"Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)",0,"Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)"
NCT04703686,Negative serologic or PCR test results for acute or chronic HBV infection Note: Patients whose HBV infection status cannot be determined by serologic test results must be negative for HBV by PCR to be eligible for study participation,0,Negative serologic or PCR test results for acute or chronic HBV infection Note: Patients whose HBV infection status cannot be determined by serologic test results must be negative for HBV by PCR to be eligible for study participation
NCT02431988,Age 16-65 years,0,Age 16-65 years
NCT05415475,No serious mental disorder;,1,No serious mental disorder
NCT03881761,CD19/CD20 positive relapsed/refractory B cell lymphoma,0,CD19/CD20 positive relapsed/refractory B cell lymphoma
NCT03758417,"
Received at least 3 prior lines of treatment for multiple myeloma
a) Undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen
",0,"Received at least 3 prior lines of treatment for multiple myeloma a) Undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen"
NCT05633615,STEP 2: RANDOMIZATION: AST and ALT =< 3 x institutional ULN (within 7 days prior to step 2 randomization),0,STEP 2: RANDOMIZATION: AST and ALT =< 3 x institutional ULN (within 7 days prior to step 2 randomization)
NCT04156178,"Ages Eligible for Study: Child, Adult, Older Adult",0,"Ages Eligible for Study: Child, Adult, Older Adult"
NCT04385173,Blood cell count： White blood count (WBC) >= 2000/μL；Neutrophil count >= 1500/μL；Platelets >= 100 x 103/μL；Hemoglobin >= 9.0 g/dL,1,Blood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.0 g/dL
NCT04442022,Sexes Eligible for Study: All,1,Sexes Eligible for Study: All
NCT04003168,Those who relapse 90 days after stem cell transplantation,0,Those who relapse 90 days after stem cell transplantation
NCT03768310,Hemoglobin >7.0 (can be a transfused value),0,Hemoglobin >7.0 (can be a transfused value)
NCT03931720,"Ages Eligible for Study: 18 Years to 75 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)"
NCT04691713,Age 3-70,0,Age 3-70
NCT05312801,Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.,0,Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.
NCT05472610,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT02259556,"Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.",0,"Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin."
NCT05574114,"Adequate bone marrow function without a requirement for blood product transfusion or growth factor support in the previous 7 days, unless the cytopenias are felt to be due to the underlying lymphoma in the best judgement of the study investigator:",0,"Adequate bone marrow function without a requirement for blood product transfusion or growth factor support in the previous 7 days, unless the cytopenias are felt to be due to the underlying lymphoma in the best judgement of the study investigator:"
NCT04863066,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04928105,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04510051,Research participant must have appropriate venous access,0,Research participant must have appropriate venous access
NCT02850536,Patient failed at least one line of standard systemic chemotherapy and has unresectable disease.,1,Patient failed at least one line of standard systemic chemotherapy and has unresectable disease.
NCT05032820,Hepatic Function: a. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x upper limit of normal (ULN) b. Serum total bilirubin less than or equal to 2 x ULN. Patients who have been diagnosed with Gilbert's disease are permitted to exceed the defined bilirubin value of 2 x ULN,0,Hepatic Function: a. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x upper limit of normal (ULN) b. Serum total bilirubin less than or equal to 2 x ULN. Patients who have been diagnosed with Gilbert's disease are permitted to exceed the defined bilirubin value of 2 x ULN
NCT04191941,At least one clear indicator for hematological malignancy monitoring;,0,At least one clear indicator for hematological malignancy monitoring
NCT03064269,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02792114,Any major operation must have occurred at least 28 days before study enrollment.,0,Any major operation must have occurred at least 28 days before study enrollment.
NCT03233854,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT03631576,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04976218,Age from 18 to 75 years with estimated life expectancy >3 months.,0,Age from 18 to 75 years with estimated life expectancy >3 months.
NCT05515185,"
Laboratory test results should at least meet the following requirements:
Left ventricular ejection fraction ≥40%; Creatinine ≤200 umol/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L; Hemoglobin ≥80g/L; Oxygen saturation of blood 91%; Total bilirubin ≤2×ULN; ALT and AST 2.5 x ULN or less; The criteria for abnormal ALT and AST due to disease (e.g., liver metastases or bile duct obstruction) or Gilbert syndrome can be relaxed to ≤5×ULN.
",1,"Laboratory test results should at least meet the following requirements: Left ventricular ejection fraction ≥40%; Creatinine ≤200 umol/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L; Hemoglobin ≥80g/L; Oxygen saturation of blood 91%; Total bilirubin ≤2×ULN; ALT and AST 2.5 x ULN or less; The criteria for abnormal ALT and AST due to disease (e.g., liver metastases or bile duct obstruction) or Gilbert syndrome can be relaxed to ≤5×ULN."
NCT02782351,Free of leukocytes removal contraindications,0,Free of leukocytes removal contraindications
NCT05239689,"Ages Eligible for Study: Child, Adult, Older Adult",0,"Ages Eligible for Study: Child, Adult, Older Adult"
NCT04007978,"
B-cell malignancies include the following three types
A. B-cell acute lymphoblastic leukemia (B-ALL)
B. Indolent B-cell lymphoma (CLL, FL, MZL, LPL, HCL)
C. Invasive B-cell lymphoma (DLBCL, BL, MCL)
",0,"B-cell malignancies include the following three types A. B-cell acute lymphoblastic leukemia (B-ALL) B. Indolent B-cell lymphoma (CLL, FL, MZL, LPL, HCL) C. Invasive B-cell lymphoma (DLBCL, BL, MCL)"
NCT05381181,"Patients cannot benefit from autologous CAR-T cell therapy due to T cell separation failure or CART amplification failure in the preparation of autologous CART, or the failure to complete apheresis or disease progression; Or the content of T cells in PBMC of peripheral blood is less than or equal to 10%; Or the disease is not effectively controlled within one month after autologous CAR-T transfusion, and the patient cannot receive CAR-T transfusion again;",0,"Patients cannot benefit from autologous CAR-T cell therapy due to T cell separation failure or CART amplification failure in the preparation of autologous CART, or the failure to complete apheresis or disease progression; Or the content of T cells in PBMC of peripheral blood is less than or equal to 10%; Or the disease is not effectively controlled within one month after autologous CAR-T transfusion, and the patient cannot receive CAR-T transfusion again"
NCT05385263,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT04715191,Refractory or relapsed disease after treatment with up- front therapy and at least one salvage treatment cycle,0,Refractory or relapsed disease after treatment with up- front therapy and at least one salvage treatment cycle
NCT03289455,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02813837,"Ages Eligible for Study: up to 60 Years   (Child, Adult)",0,"Ages Eligible for Study: up to 60 Years (Child, Adult)"
NCT04864821,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05149391,CD19 or CD20 positive B-Non-Hodgkin's lymphoma confirmed by cytology or histology according to World Health Organization 2016 criteria;,1,CD19 or CD20 positive B-Non-Hodgkin's lymphoma confirmed by cytology or histology according to World Health Organization 2016 criteria
NCT04655677,Expected survival ≥ 12 weeks,0,Expected survival ≥ 12 weeks
NCT04840875,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04429451,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03994913,The Eastern Cooperative Oncology Group (ECOG) score is 0 or 1 point;,0,The Eastern Cooperative Oncology Group (ECOG) score is 0 or 1 point
NCT05495464,Newly diagnosed high risk patient without any prior therapy for MCL and are eligible to receive AR and CART cell therapy.,1,Newly diagnosed high risk patient without any prior therapy for MCL and are eligible to receive AR and CART cell therapy.
NCT04599556,The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.,0,The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.
NCT05225831,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05429905,"<p>Cohort 3 (Phase II): Relapsed/Refractory Extramedullary B-ALL</p><ul><ul>
<li>Patients with testicular leukaemia confirmed on biopsy</li>
<li>Patients with CNS-3 B-ALL or Leptomeningeal disease</li>
<li>Patients with combined bone marrow and extramedullary relapse (as defined in Cohort 1) are eligible.</li>
</ul></ul>",0,<p>Cohort 3 (Phase II): Relapsed/Refractory Extramedullary B-ALL</p><ul><ul> <li>Patients with testicular leukaemia confirmed on biopsy</li> <li>Patients with CNS-3 B-ALL or Leptomeningeal disease</li> <li>Patients with combined bone marrow and extramedullary relapse (as defined in Cohort 1) are eligible.</li> </ul></ul>
NCT04511871,"Capable of receiving treatment and follow-up, including treatment in the clinical center;",0,"Capable of receiving treatment and follow-up, including treatment in the clinical center"
NCT05432635,Absolute neutrophil count >= 1000/uL (Transfusions and growth factors must not be used to meet this requirement at initial screening),0,Absolute neutrophil count >= 1000/uL (Transfusions and growth factors must not be used to meet this requirement at initial screening)
NCT05077527,"Men who have partners of childbearing potential must agree to use an effective barrier contraceptive method before study entry, for the duration of study participation, and for 1 year after the last dose of axicabtagene ciloleucel",0,"Men who have partners of childbearing potential must agree to use an effective barrier contraceptive method before study entry, for the duration of study participation, and for 1 year after the last dose of axicabtagene ciloleucel"
NCT03980288,Expected survival is > 12 weeks;,0,Expected survival is > 12 weeks
NCT04938115,HGB≥70g/L (can be transfused);,0,HGB≥70g/L (can be transfused)
NCT04778579,Life expectancy of at least 3 months.,0,Life expectancy of at least 3 months.
NCT03881774,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03904069,Karnofsky performance score greater than or equal to 50 (for subjects aged greater than or equal to 16 years) or Lansky (for subjects aged less than 16 years) performance score greater than or equal to 50.,0,Karnofsky performance score greater than or equal to 50 (for subjects aged greater than or equal to 16 years) or Lansky (for subjects aged less than 16 years) performance score greater than or equal to 50.
NCT05287165,Tumor tissue samples were positive for GUCY2C IHC staining;,0,Tumor tissue samples were positive for GUCY2C IHC staining
NCT04442022,"Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy).",1,"Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy)."
NCT02631044,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02710149,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02208362,Research participant serum total bilirubin does not exceed 2 x normal limit,0,Research participant serum total bilirubin does not exceed 2 x normal limit
NCT05418088,"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the Anti-CD19/20/22 CAR-T cell infusion. Men must refrain from donating sperm during this same period",1,"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the Anti-CD19/20/22 CAR-T cell infusion. Men must refrain from donating sperm during this same period"
NCT04817774,Male or female aged 18 - 70 years.,1,Male or female aged 18 - 70 years.
NCT03937544,Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not receiving immunosuppression,1,Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not receiving immunosuppression
NCT04429451,Body weight greater than or equal to 10 kg.,0,Body weight greater than or equal to 10 kg.
NCT04499573,"Patient cardiac function left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.",0,"Patient cardiac function left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO."
NCT05514327,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05422521,Affiliated patient or beneficiary of a social security scheme,0,Affiliated patient or beneficiary of a social security scheme
NCT04134325,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04336501,It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation,0,It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation
NCT03356795,"GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry.",0,"GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry."
NCT05538195,"Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;",0,"Have apheresis or venous blood collection standards, and have no other contraindications for cell collection"
NCT04767308,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03798509,ECOG score 0-1;,0,ECOG score 0-1
NCT04271410,Left ventricular ejection fraction ≥50%,0,Left ventricular ejection fraction ≥50%
NCT05243212,Able to understand and sign the Informed Consent Document.,0,Able to understand and sign the Informed Consent Document.
NCT05269914,Adequate organ function.,0,Adequate organ function.
NCT03938987,"Tumor tissue (archival or recent acquisition) must be available for correlative laboratory studies (such as immunohistochemistry, and others).",0,"Tumor tissue (archival or recent acquisition) must be available for correlative laboratory studies (such as immunohistochemistry, and others)."
NCT04627740,PS 0-2,0,PS 0-2
NCT02842138,life expectancy > 3months.,0,life expectancy > 3months.
NCT04599543,Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.,0,Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.
NCT03117751,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03545815,Life expectancy > 12 weeks.,0,Life expectancy > 12 weeks.
NCT05234190,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03528421,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT04550663,Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration;,1,Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration
NCT03380039,"Ages Eligible for Study: 18 Years to 70 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT04013802,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04812691,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04648475,"Ages Eligible for Study: 3 Years to 75 Years   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 3 Years to 75 Years (Child, Adult, Older Adult)"
NCT02721407,"Ages Eligible for Study: 18 Years to 70 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT04662294,"<p>Inclusion criteria only for AML:</p><ol>
<li>Histologically confirmed diagnosis of CD70 AML per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);</li>
<li>
<p>Relapsed or refractory CD70+ AML (meeting one of the following conditions):</p>
<ol>
<li>CR not achieved after standardized chemotherapy;</li>
<li>CR achieved following the first induction, but CR duration is less than 12 months;</li>
<li>Ineffectively after first or multiple remedial treatments;</li>
<li>2 or more relapses;</li>
</ol>
</li>
<li>The number of primordial cells in bone marrow is &gt; 5% (by morphology), and/or &gt; 0.01% (by flowcytometry);</li>
<li>Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;</li>
<li>Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;</li>
<li>No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;</li>
<li>Estimated survival time ≥ 3 months;</li>
<li>ECOG performance status 0 to 2;</li>
<li>Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.</li>
</ol>",0,"<p>Inclusion criteria only for AML:</p><ol> <li>Histologically confirmed diagnosis of CD70 AML per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);</li> <li> <p>Relapsed or refractory CD70+ AML (meeting one of the following conditions):</p> <ol> <li>CR not achieved after standardized chemotherapy;</li> <li>CR achieved following the first induction, but CR duration is less than 12 months;</li> <li>Ineffectively after first or multiple remedial treatments;</li> <li>2 or more relapses;</li> </ol> </li> <li>The number of primordial cells in bone marrow is > 5% (by morphology), and/or > 0.01% (by flowcytometry);</li> <li>Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;</li> <li>Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;</li> <li>No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;</li> <li>Estimated survival time ≥ 3 months;</li> <li>ECOG performance status 0 to 2;</li> <li>Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.</li> </ol>"
NCT05290155,"Relapsed and refractory patients with diagnosis of CD7 positive T cell lymphoma have had≥2 prior lines of therapy,who do not acheive at least a PR, or have a relapse including:a. Peripheral T cell lymphoma NOS, or b.Angioimmunoblastic T cell lymphoma,or c. Anaplastic large cell lymphoma c.Disease can be assessed(BM or CT scan)",0,"Relapsed and refractory patients with diagnosis of CD7 positive T cell lymphoma have had≥2 prior lines of therapy,who do not acheive at least a PR, or have a relapse including:a. Peripheral T cell lymphoma NOS, or b.Angioimmunoblastic T cell lymphoma,or c. Anaplastic large cell lymphoma c.Disease can be assessed(BM or CT scan)"
NCT04703686,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT01683279,absolute lymphocyte count of >/=750 cell/mm3 or >/=500 is >20kg,0,absolute lymphocyte count of >/=750 cell/mm3 or >/=500 is >20kg
NCT02735291,"All patients with acute non T lymphocytic leukemia after conventional treatment is invalid or recurrence of refractory, and by flow cytometry or pathological immunohistochemical examination, confirm the leukemia cells express can intervene molecular targets;",0,"All patients with acute non T lymphocytic leukemia after conventional treatment is invalid or recurrence of refractory, and by flow cytometry or pathological immunohistochemical examination, confirm the leukemia cells express can intervene molecular targets"
NCT04483778,Participants age ≤ 26 years at the time of consent for study participation; the first 2 participants enrolled and treated with CAR T cells in both Arms A and B will be ≥ 15 years. and ≤ 26 years at time of consent for study participation,0,Participants age ≤ 26 years at the time of consent for study participation; the first 2 participants enrolled and treated with CAR T cells in both Arms A and B will be ≥ 15 years. and ≤ 26 years at time of consent for study participation
NCT04792489,"If has history of cerebral vascular accident (CVA), the CVA event must be greater than 12 months prior to leukapheresis. Any neurological deficits must be stable.",1,"If has history of cerebral vascular accident (CVA), the CVA event must be greater than 12 months prior to leukapheresis. Any neurological deficits must be stable."
NCT05287165,Adequate organ function;,0,Adequate organ function
NCT03366324,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT05412329,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03265106,"Not eligible for allogeneic SCT because of age, comorbid disease, or lack of available family member or unrelated donor",1,"Not eligible for allogeneic SCT because of age, comorbid disease, or lack of available family member or unrelated donor"
NCT05654077,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05131763,"Disease must be measurable according to the corresponding guidelines,",0,"Disease must be measurable according to the corresponding guidelines,"
NCT02933775,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT02729493,The lymphocyte count must > =0.4*10^9/L at the time of collection of peripheral blood;,0,The lymphocyte count must > =0.4*10^9/L at the time of collection of peripheral blood
NCT05436223,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05474885,"AST/ALT below 3 times the upper limit of normal, blood bilirubin <34.2 μmol/L (2.0 mg/dl);",1,"AST/ALT below 3 times the upper limit of normal, blood bilirubin <34.2 μmol/L (2.0 mg/dl)"
NCT04048434,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT02772198,Adequate CD3 count (above 250 CD3+ cells per microliter blood),0,Adequate CD3 count (above 250 CD3+ cells per microliter blood)
NCT05470777,expected survival > 3 months.,0,expected survival > 3 months.
NCT04952272,Life expectancy is greater than three months,0,Life expectancy is greater than three months
NCT02725125,"Voluntary participation, good compliance,the subjects can cooperate with the experimental observation, and signed a written Informed Consent Form;",1,"Voluntary participation, good compliance,the subjects can cooperate with the experimental observation, and signed a written Informed Consent Form"
NCT05377827,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04539444,Age ≥ 18 years,0,Age ≥ 18 years
NCT05032820,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT05298995,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT05538195,No serious mental disorder;,0,No serious mental disorder
NCT03330691,Life expectancy of at least 8 weeks,0,Life expectancy of at least 8 weeks
NCT03790891,"Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB>70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);",1,"Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB>70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome)"
NCT02690545,Karnofsky or Lansky score of >60% (Karnofsky for ≥16 years old and Lansky for <16 years old),1,Karnofsky or Lansky score of >60% (Karnofsky for ≥16 years old and Lansky for <16 years old)
NCT04506983,ECOG is 0 or 1 (one week before enrollment.),0,ECOG is 0 or 1 (one week before enrollment.)
NCT04981691,Ability to understand and the willingness to provide written informed consent.,0,Ability to understand and the willingness to provide written informed consent.
NCT04422912,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT05143112,The ECOG behavior status score is 0-2 points;,0,The ECOG behavior status score is 0-2 points
NCT02710149,Ability to give informed consent.,0,Ability to give informed consent.
NCT05416554,>/= 18 years-old,0,>/= 18 years-old
NCT04981691,IHC test showed Mesothelin positive expression at least 1+ in tumor tissue,0,IHC test showed Mesothelin positive expression at least 1+ in tumor tissue
NCT05277987,According to the solid tumor efficacy evaluation standard (RECIST) v1.1Measurable lesions;,0,According to the solid tumor efficacy evaluation standard (RECIST) v1.1Measurable lesions
NCT04430595,"Ages Eligible for Study: 18 Years to 75 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)"
NCT05085418,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04989803,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT05416554,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04447573,The expression of BCMA in myeloma cells was reported as positive by flow cytometry or immunohistochemistry;,0,The expression of BCMA in myeloma cells was reported as positive by flow cytometry or immunohistochemistry
NCT04544592,"Males OR non-pregnant, non-lactating females",1,"Males OR non-pregnant, non-lactating females"
NCT04684472,Male and female of reproductive potential must agree to use birth control during the study and for at least 30 days post study;,1,Male and female of reproductive potential must agree to use birth control during the study and for at least 30 days post study
NCT04412889,"Females must not be in pregnancy nor in lactation. Form signing the ICF to the end of the trial, females of childbearing potential and males must use efficient contraception;",1,"Females must not be in pregnancy nor in lactation. Form signing the ICF to the end of the trial, females of childbearing potential and males must use efficient contraception"
NCT01583686,Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.,0,Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
NCT05371132,Participant is willing and able to comply with all protocol required procedures,0,Participant is willing and able to comply with all protocol required procedures
NCT05306080,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT03814447,Able to understand and sign the Informed Consent Document.,0,Able to understand and sign the Informed Consent Document.
NCT04318327,"Part B: Subjects with newly diagnosed multiple myeloma (NDMM) who have received a minimum of 4 and up to 6 cycles of standard induction therapy with VRd, D-VRd, or D-Rd, and have achieved a response of PR or better. One cycle of CyBorDex is allowed prior to induction.",0,"Part B: Subjects with newly diagnosed multiple myeloma (NDMM) who have received a minimum of 4 and up to 6 cycles of standard induction therapy with VRd, D-VRd, or D-Rd, and have achieved a response of PR or better. One cycle of CyBorDex is allowed prior to induction."
NCT02644655,At least two months after infusion of T cells,0,At least two months after infusion of T cells
NCT05341492,1.All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure;,0,All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure
NCT04789408,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02631044,PET-positive disease by Lugano classification,0,PET-positive disease by Lugano classification
NCT05353530,"<p>0 = Negative</p><ol>
<li>= Low level</li>
<li>= Moderate level</li>
<li>
<p>= High level</p>
<ul>
<li>
<p>The criteria for inclusion will be at least 20% of the cells scoring 1+ staining intensity (&gt; 20%, 1+).</p>
<ul>
<li>Surgical resection of tumors with less than 3cm x 3cm (9 cm2) residual enhancing tumor as a product of longest perpendicular planes by MRI. (biopsy only subjects are not eligible for this study)</li>
<li>Karnofsky Performance Status (KPS) of &gt; 70%</li>
<li>CBC with differential with adequate bone marrow function as defined below:</li>
</ul>
</li>
<li>Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.</li>
<li>Platelet count ≥ 100,000 cells/mm3.</li>
<li>
<p>Hemoglobin ≥ 10 g/dl. (The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)</p>
<p>• Adequate renal function as defined below:</p>
</li>
<li>BUN ≤ 25 mg/dl</li>
<li>
<p>Creatinine ≤ 1.7 mg/dl</p>
<p>• Adequate hepatic function as defined below:</p>
</li>
<li>Bilirubin ≤ 2.0 mg/dl</li>
<li>ALT ≤ 5 times institutional upper limits of normal for age</li>
<li>
<p>AST ≤ 5 times institutional upper limits of normal for age</p>
<ul>
<li>Signed informed consent. If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the legally authorized representative.</li>
<li>For females of childbearing potential, a negative serum pregnancy test at enrollment.</li>
<li>Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.</li>
<li>Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.</li>
</ul>
</li>
</ul>
</li>
</ol>",1,"<p>0 = Negative</p><ol> <li>= Low level</li> <li>= Moderate level</li> <li> <p>= High level</p> <ul> <li> <p>The criteria for inclusion will be at least 20% of the cells scoring 1+ staining intensity (> 20%, 1+).</p> <ul> <li>Surgical resection of tumors with less than 3cm x 3cm (9 cm2) residual enhancing tumor as a product of longest perpendicular planes by MRI. (biopsy only subjects are not eligible for this study)</li> <li>Karnofsky Performance Status (KPS) of > 70%</li> <li>CBC with differential with adequate bone marrow function as defined below:</li> </ul> </li> <li>Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.</li> <li>Platelet count ≥ 100,000 cells/mm3.</li> <li> <p>Hemoglobin ≥ 10 g/dl. (The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)</p> <p>• Adequate renal function as defined below:</p> </li> <li>BUN ≤ 25 mg/dl</li> <li> <p>Creatinine ≤ 1.7 mg/dl</p> <p>• Adequate hepatic function as defined below:</p> </li> <li>Bilirubin ≤ 2.0 mg/dl</li> <li>ALT ≤ 5 times institutional upper limits of normal for age</li> <li> <p>AST ≤ 5 times institutional upper limits of normal for age</p> <ul> <li>Signed informed consent. If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the legally authorized representative.</li> <li>For females of childbearing potential, a negative serum pregnancy test at enrollment.</li> <li>Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.</li> <li>Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.</li> </ul> </li> </ul> </li> </ol>"
NCT02723942,GPC3 high expression hepatocellular carcinoma patients.,0,GPC3 high expression hepatocellular carcinoma patients.
NCT03030001,6. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.,0,6. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
NCT04981691,"Ages Eligible for Study: 18 Years to 80 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)"
NCT04196413,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03993743,Patient with histologically confirmed diagnosis of CD147+ hepatocellular carcinoma.,0,Patient with histologically confirmed diagnosis of CD147+ hepatocellular carcinoma.
NCT00889954,"Ages Eligible for Study: 3 Years and older   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 3 Years and older (Child, Adult, Older Adult)"
NCT04626752,"The subjects had no pulmonary infection, normal pulmonary function, and indoor air oxygen saturation ≥92%;",1,"The subjects had no pulmonary infection, normal pulmonary function, and indoor air oxygen saturation ≥92%"
NCT04888442,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05030779,"Ages Eligible for Study: Child, Adult, Older Adult",0,"Ages Eligible for Study: Child, Adult, Older Adult"
NCT03483688,Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography).,0,Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography).
NCT05105152,"<li>
<p>If a subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of DARIC T cells, the subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy:</p>
<p>a. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued ≥ 7 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period b. Must be ≥ 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued ≥ 7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be discontinued ≥ 3 days prior to enrollment e. Hydroxyurea: must be discontinued ≥ 1 day prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR ii. must be at least 60 days from most recent gene modified cell therapy</p>
</li>",1,"<li> <p>If a subject does not have a previously obtained apheresis product that is acceptable and available for manufacturing of DARIC T cells, the subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy:</p> <p>a. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued ≥ 7 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period b. Must be ≥ 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued ≥ 7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be discontinued ≥ 3 days prior to enrollment e. Hydroxyurea: must be discontinued ≥ 1 day prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR ii. must be at least 60 days from most recent gene modified cell therapy</p> </li>"
NCT03018093,Morphological disease in the bone marrow (≥ 5% blasts).,0,Morphological disease in the bone marrow (≥ 5% blasts).
NCT05404048,"If has history of central nervous system (CNS) disease, then must have no signs or symptoms of CNS disease, no active disease on magnetic resonance imaging (MRI) and absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells.",0,"If has history of central nervous system (CNS) disease, then must have no signs or symptoms of CNS disease, no active disease on magnetic resonance imaging (MRI) and absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells."
NCT02958397,"Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.",0,"Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis."
NCT03110640,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT01818323,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04196205,"Ages Eligible for Study: 18 Years to 70 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT04007029,Minimum tumor burden of 1.5 cm^3 for lymphoma,0,Minimum tumor burden of 1.5 cm^3 for lymphoma
NCT05028933,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05325801,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04271410,All genders ，ages: 2 to 75 years；,0,"All genders ,ages: 2 to 75 years"
NCT05480501,Adequate organ function.,0,Adequate organ function.
NCT02445222,"Ages Eligible for Study: Child, Adult, Older Adult",0,"Ages Eligible for Study: Child, Adult, Older Adult"
NCT05585996,Life expectancy ≥ 3 months;,0,Life expectancy ≥ 3 months
NCT04817774,Written informed consent.,0,Written informed consent.
NCT04897321,"Ages Eligible for Study: up to 21 Years   (Child, Adult)",0,"Ages Eligible for Study: up to 21 Years (Child, Adult)"
NCT03563326,"Patients with EpCAM positive gastric cancer who have peritoneal metastasis at first visit; Patients with highly suspected or previous proven peritoneal metastasis by biopsy, CT, digital rectal examination, etc. who failed to the routine therapies like chemotherapy;",1,"Patients with EpCAM positive gastric cancer who have peritoneal metastasis at first visit; Patients with highly suspected or previous proven peritoneal metastasis by biopsy, CT, digital rectal examination, etc. who failed to the routine therapies like chemotherapy"
NCT03585764,Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining).,0,Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining).
NCT03884751,Understand and sign informed consent.,0,Understand and sign informed consent.
NCT02028455,Patients must be free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollment.,0,Patients must be free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollment.
NCT05117008,Spot urine (albumin/creatinine ratio) < 500 mg/g (56 mg/mmol) OR urine dipstick negative/trace (if ≥ 1+ only eligible if confirmed < 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void).,0,Spot urine (albumin/creatinine ratio) < 500 mg/g (56 mg/mmol) OR urine dipstick negative/trace (if ≥ 1+ only eligible if confirmed < 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void).
NCT04890236,Alanine aminotransferase (AST)/aspartate aminotransferase (ALT) < 2 x upper limit of normal (ULN),0,Alanine aminotransferase (AST)/aspartate aminotransferase (ALT) < 2 x upper limit of normal (ULN)
NCT04410900,"CARTx RECIPIENTS: Patients must be 18 years of age or older, of any gender, race or ethnicity",1,"CARTx RECIPIENTS: Patients must be 18 years of age or older, of any gender, race or ethnicity"
NCT03330691,"<li>
<p>Disease status:</p>
<ul>
<li>If post allogeneic HCT: Confirmed CD19+CD22+ leukemia recurrence defined as at least 0.01% disease following allogeneic HCT</li>
<li>If relapse/refractory status with no prior history of allogeneic HCT, one of the following:</li>
<li>Second or greater marrow relapse, with or without extramedullary disease</li>
<li>First marrow relapse at end of first month or re-induction with marrow having at least 0.01 % blasts by morphology and/or MPF</li>
<li>Primary refractory as defined as greater than 5% blasts by multi-parameter flow after at least 2 separate induction regimens.</li>
<li>Subject has indication for HCT but has been deemed ineligible, inclusive of persistent MRD prior to HCT</li>
</ul>
</li>",0,"<li> <p>Disease status:</p> <ul> <li>If post allogeneic HCT: Confirmed CD19+CD22+ leukemia recurrence defined as at least 0.01% disease following allogeneic HCT</li> <li>If relapse/refractory status with no prior history of allogeneic HCT, one of the following:</li> <li>Second or greater marrow relapse, with or without extramedullary disease</li> <li>First marrow relapse at end of first month or re-induction with marrow having at least 0.01 % blasts by morphology and/or MPF</li> <li>Primary refractory as defined as greater than 5% blasts by multi-parameter flow after at least 2 separate induction regimens.</li> <li>Subject has indication for HCT but has been deemed ineligible, inclusive of persistent MRD prior to HCT</li> </ul> </li>"
NCT04599543,Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;,0,Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%
NCT05325801,ECOG 0-2;,0,ECOG 0-2
NCT04007029,Must be willing and able to provide written informed consent,0,Must be willing and able to provide written informed consent
NCT04119024,"Must have received at least one prior systemic therapy for advanced melanoma (i.e. anti-PD-1 therapy, BRAF plus MEK inhibitor therapy for BRAFV600 mutated melanoma) and is not considered to have an alternate treatment option with curative intent",1,"Must have received at least one prior systemic therapy for advanced melanoma (i.e. anti-PD-1 therapy, BRAF plus MEK inhibitor therapy for BRAFV600 mutated melanoma) and is not considered to have an alternate treatment option with curative intent"
NCT02159495,"ARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 line of systemic therapy for BPDCN and who have persistent or recurrent disease in at least one of the following are eligible: peripheral blood, bone marrow, lymph nodes, spleen, cutaneous lesions or other sites OR participant who are at high risk for disease recurrence",0,"ARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 line of systemic therapy for BPDCN and who have persistent or recurrent disease in at least one of the following are eligible: peripheral blood, bone marrow, lymph nodes, spleen, cutaneous lesions or other sites OR participant who are at high risk for disease recurrence"
NCT05364424,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05277753,"Expression of CD7, CD5, CD317, CD47, CD99, CD38 or TRBC1/2 is determined in malignant cells by flow cytometry or immuno-histochemical staining.",0,"Expression of CD7, CD5, CD317, CD47, CD99, CD38 or TRBC1/2 is determined in malignant cells by flow cytometry or immuno-histochemical staining."
NCT03159819,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04429451,At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody.,0,At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody.
NCT03874897,"ECOG physical status score 0 ~ 1, within 24 hours prior to apheresis, and at baseline (prior to pre-treatment);",0,"ECOG physical status score 0 ~ 1, within 24 hours prior to apheresis, and at baseline (prior to pre-treatment)"
NCT03198546,Life expectancy >12 weeks,0,Life expectancy >12 weeks
NCT03853616,Male or female patients must have r/r CD19-expressing ALL or NHL/CLL,1,Male or female patients must have r/r CD19-expressing ALL or NHL/CLL
NCT02274584,Hb≥80g/L,0,Hb≥80g/L
NCT04133636,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT05489991,Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.,0,Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
NCT04782193,Signed written informed consent,0,Signed written informed consent
NCT03765177,"<li>
<p>Participant must have relapsed or refractory CD19+ disease as defined by one of the following:</p>
<p>a. Relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia as defined by one of the following: i. Second or greater relapse ii. Any relapse after allogeneic stem cell transplantation (SCT) iii. Chemorefractory as defined by not achieving CR after 2 cycles of a standard induction chemotherapy or one cycle of salvage therapy b. Histologically confirmed B-cell non-Hodgkin's lymphoma including but not limited to diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, or transformed follicular lymphoma, Richter's, Burkitt's or Mantle Cell lymphoma with one of the following: i. Second or greater relapse ii. Any relapse after autologous or allogeneic SCT iii. Chemorefractory as defined by not achieving CR after 2 cycles of a standard chemotherapy or one cycle of salvage therapy</p>
</li>",0,"<li> <p>Participant must have relapsed or refractory CD19+ disease as defined by one of the following:</p> <p>a. Relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia as defined by one of the following: i. Second or greater relapse ii. Any relapse after allogeneic stem cell transplantation (SCT) iii. Chemorefractory as defined by not achieving CR after 2 cycles of a standard induction chemotherapy or one cycle of salvage therapy b. Histologically confirmed B-cell non-Hodgkin's lymphoma including but not limited to diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, or transformed follicular lymphoma, Richter's, Burkitt's or Mantle Cell lymphoma with one of the following: i. Second or greater relapse ii. Any relapse after autologous or allogeneic SCT iii. Chemorefractory as defined by not achieving CR after 2 cycles of a standard chemotherapy or one cycle of salvage therapy</p> </li>"
NCT04973527,"Ages Eligible for Study: 18 Years to 75 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)"
NCT02876978,"Ages Eligible for Study: 18 Years to 70 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)"
NCT04154709,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04377932,"Ages Eligible for Study: 1 Year to 21 Years   (Child, Adult)",0,"Ages Eligible for Study: 1 Year to 21 Years (Child, Adult)"
NCT04045847,Patients with entirely informed consent and voluntarily sign the informed consent by themselves or their legal representative.,0,Patients with entirely informed consent and voluntarily sign the informed consent by themselves or their legal representative.
NCT04185038,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03579888,RECIPIENT: Patient able to provide written informed consent for the long-term follow-up (LTFU) gene therapy study,0,RECIPIENT: Patient able to provide written informed consent for the long-term follow-up (LTFU) gene therapy study
NCT04989803,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT04617704,"Liver, kidney and cardiopulmonary functions meet the following requirements: a) Total bilirubin less than or equal to 2*ULN(except for Gilbert Syndrome); ALT and AST less than or equal to 2.5*ULN, maintenance of kidney function not depend on dialysis; c)Corrected serum calcium less than or equal to 12.5 mg/dL or free ion calcium less than or equal to 6.5mg/dL(1.6mmol/L);",1,"Liver, kidney and cardiopulmonary functions meet the following requirements: a) Total bilirubin less than or equal to 2*ULN(except for Gilbert Syndrome); ALT and AST less than or equal to 2.5*ULN, maintenance of kidney function not depend on dialysis; c)Corrected serum calcium less than or equal to 12.5 mg/dL or free ion calcium less than or equal to 6.5mg/dL(1.6mmol/L)"
NCT03661554,Patients agreed to participate in the clinical study and signed the informed consent form.,0,Patients agreed to participate in the clinical study and signed the informed consent form.
NCT05631912,"Ages Eligible for Study: 18 Years to 75 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)"
NCT04706936,BCMA expression ≥50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression;,0,BCMA expression ≥50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression
NCT05123209,"≥ 18 years old, male or female.",1,"≥ 18 years old, male or female."
NCT05052528,"For females of reproductive potential: use of highly effective contraception (oral contraceptives, intrauterine device) during screening confirmed with serum pregnancy test, and agreement to use such a method during study participation and for an additional 4 weeks after the end of CD19 CAR T cell infusion",0,"For females of reproductive potential: use of highly effective contraception (oral contraceptives, intrauterine device) during screening confirmed with serum pregnancy test, and agreement to use such a method during study participation and for an additional 4 weeks after the end of CD19 CAR T cell infusion"
NCT05633615,"STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with current symptoms of cardiac disease must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better",0,"STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): Participants with current symptoms of cardiac disease must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better"
NCT03191773,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04561557,All acute toxic reactions resolved to baseline or ≤ grade 1 assessed using NCI-CTCAE v5.0 except the ones adjudicated by the investigator to pose no risks on subjects.,0,All acute toxic reactions resolved to baseline or ≤ grade 1 assessed using NCI-CTCAE v5.0 except the ones adjudicated by the investigator to pose no risks on subjects.
NCT05451212,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03599375,Hemoglobin(Hgb)≥80g/L,0,Hemoglobin(Hgb)≥80g/L
NCT05098613,"<li>
<p>Histologically confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008:</p>
<ol>
<li>Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR</li>
<li>Primary mediastinal (thymic) large B cell lymphoma; OR</li>
<li>Transformation to DLBCL will also be included.</li>
<li>Subjects must not have signs or symptoms of CNS disease or detectable evidence of CNS disease on magnetic resonance imaging (MRI) at screening; subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible.</li>
</ol>
</li>",1,"<li> <p>Histologically confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008:</p> <ol> <li>Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR</li> <li>Primary mediastinal (thymic) large B cell lymphoma; OR</li> <li>Transformation to DLBCL will also be included.</li> <li>Subjects must not have signs or symptoms of CNS disease or detectable evidence of CNS disease on magnetic resonance imaging (MRI) at screening; subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible.</li> </ol> </li>"
NCT04712864,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03064269,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04412889,Measurable disease at screening as defined by any of the following: 1) Serum monoclonal paraprotein (M-protein) level ≥10 g/L or urine M-protein level ≥200 mg/24 hours or; 2) Light chain MM without measurable disease in the serum or the urine: serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio or; 3) Plasma cell percentage in bone marrow ≥30%;,1,Measurable disease at screening as defined by any of the following: 1) Serum monoclonal paraprotein (M-protein) level ≥10 g/L or urine M-protein level ≥200 mg/24 hours or; 2) Light chain MM without measurable disease in the serum or the urine: serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio or; 3) Plasma cell percentage in bone marrow ≥30%
NCT03706547,The ALT/AST value is lower than 2.5-fold of normal value,1,The ALT/AST value is lower than 2.5-fold of normal value
NCT04385173,>= 14 days after completion of Temozolomide or other chemotherapy,0,>= 14 days after completion of Temozolomide or other chemotherapy
NCT03751293,ECOG scores 0 - 1.,0,ECOG scores 0 - 1.
NCT03208556,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT04186520,i. A maximum of four patients with history of prior anti-CD19 CAR-T will be allowed in this cohort.,0,i. A maximum of four patients with history of prior anti-CD19 CAR-T will be allowed in this cohort.
NCT04162119,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT03602157,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT04626765,"Ages Eligible for Study: 1 Year to 18 Years   (Child, Adult)",0,"Ages Eligible for Study: 1 Year to 18 Years (Child, Adult)"
NCT05326243,"Ages Eligible for Study: 14 Years to 70 Years   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 14 Years to 70 Years (Child, Adult, Older Adult)"
NCT04796675,Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.,0,Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.
NCT04337606,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT03030001,3. Patients must have previously received at least one standard therapy for their cancer (if available) and have been either non-responders (progressive disease) or have recurred. And patients are willing to attend the clinical trial.,1,Patients must have previously received at least one standard therapy for their cancer (if available) and have been either non-responders (progressive disease) or have recurred. And patients are willing to attend the clinical trial.
NCT04443829,"Agreement to have a pregnancy test, use highly effective contraception (if applicable)",1,"Agreement to have a pregnancy test, use highly effective contraception (if applicable)"
NCT04034446,"Ages Eligible for Study: 3 Years and older   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 3 Years and older (Child, Adult, Older Adult)"
NCT05616468,1. Sign the written informed consent voluntarily;,0,Sign the written informed consent voluntarily
NCT05016778,The subject can understand and have the ability to sign an informed consent form;,0,The subject can understand and have the ability to sign an informed consent form
NCT01818323,Eastern Co-operative Oncology Performance Status of 0-2.,0,Eastern Co-operative Oncology Performance Status of 0-2.
NCT03870945,Patients in cohort 1a must have histologically confirmed DLBCL and associated subtypes with relapse or refractory disease after first line chemo-immunotherapy and be ineligible for HSCT,0,Patients in cohort 1a must have histologically confirmed DLBCL and associated subtypes with relapse or refractory disease after first line chemo-immunotherapy and be ineligible for HSCT
NCT05022849,Histology: Metastatic CRPC (mCRPC) with histologic confirmation of adenocarcinoma. Metastatic CRPC with neuroendocrine features or mixed histology is excluded,0,Histology: Metastatic CRPC (mCRPC) with histologic confirmation of adenocarcinoma. Metastatic CRPC with neuroendocrine features or mixed histology is excluded
NCT04855136,"<p>Participants must satisfy the following criteria to be enrolled in the study:</p><ul>
<li>
<p>Participant has documented diagnosis of MM and measurable disease, defined as:</p>
<ol>
<li>M-protein (serum protein electrophoresis [sPEP ≥ 0.5 g/dL] or urine protein electrophoresis [uPEP]): uPEP ≥ 200 mg/24 hours and/or</li>
<li>Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio</li>
</ol>
</li>
<li>
<p>Participant has received:</p>
<ol>
<li>at least 3 prior MM regimens for Arm A Cohort 1 and Arm B</li>
<li>at least 1 but no greater than 3 prior MM regimens for Arm A Cohort 2</li>
</ol>
</li>
<li>Arm A Cohort 1 and Arm B: Participant has received prior treatment with an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody-containing regimen for at least 2 consecutive cycles.</li>
<li>Arm A Cohort 2: Participant has received prior treatment with an immunomodulatory agent for at least 2 consecutive cycles.</li>
<li>Evidence of PD during or within 6 months (measured from the last dose of any drug within the regimen) of completing treatment with the last antimyeloma regimen before study entry.</li>
<li>Participant achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.</li>
<li>Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.</li>
</ul>",1,"<p>Participants must satisfy the following criteria to be enrolled in the study:</p><ul> <li> <p>Participant has documented diagnosis of MM and measurable disease, defined as:</p> <ol> <li>M-protein (serum protein electrophoresis [sPEP ≥ 0.5 g/dL] or urine protein electrophoresis [uPEP]): uPEP ≥ 200 mg/24 hours and/or</li> <li>Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio</li> </ol> </li> <li> <p>Participant has received:</p> <ol> <li>at least 3 prior MM regimens for Arm A Cohort 1 and Arm B</li> <li>at least 1 but no greater than 3 prior MM regimens for Arm A Cohort 2</li> </ol> </li> <li>Arm A Cohort 1 and Arm B: Participant has received prior treatment with an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody-containing regimen for at least 2 consecutive cycles.</li> <li>Arm A Cohort 2: Participant has received prior treatment with an immunomodulatory agent for at least 2 consecutive cycles.</li> <li>Evidence of PD during or within 6 months (measured from the last dose of any drug within the regimen) of completing treatment with the last antimyeloma regimen before study entry.</li> <li>Participant achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.</li> <li>Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.</li> </ul>"
NCT05240950,"Patients diagnosed with liver metastasis of colorectal cancer underwent radical surgery for the primary lesion of colorectal cancer, and R0 resection was performed for the liver metastasis (R0 resection was required for other organ metastasis). There was no measurable disease or tumor remnants (except invisible or unmeasurable disease) were found by imaging examination after surgery;",1,"Patients diagnosed with liver metastasis of colorectal cancer underwent radical surgery for the primary lesion of colorectal cancer, and R0 resection was performed for the liver metastasis (R0 resection was required for other organ metastasis). There was no measurable disease or tumor remnants (except invisible or unmeasurable disease) were found by imaging examination after surgery"
NCT04185038,"CNS reservoir catheter, such as an Ommaya or Rickham catheter",0,"CNS reservoir catheter, such as an Ommaya or Rickham catheter"
NCT04727008,ECOG ≤ 2,0,ECOG ≤ 2
NCT04853277,Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy at Dartmouth-Hitchcock Medical Center is eligible.,1,Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy at Dartmouth-Hitchcock Medical Center is eligible.
NCT05106946,"Age 18-70 years old, no gender and race limited;",1,"Age 18-70 years old, no gender and race limited"
NCT03344705,"Ages Eligible for Study: 4 Years to 75 Years   (Child, Adult, Older Adult)",0,"Ages Eligible for Study: 4 Years to 75 Years (Child, Adult, Older Adult)"
NCT03098355,Relapsed or refractory CD19+ B-cell lymphoma or leukemia.,0,Relapsed or refractory CD19+ B-cell lymphoma or leukemia.
NCT03356782,Age: ≥ 18 and ≤65 years of age at the time of enrollment;,0,Age: ≥ 18 and ≤65 years of age at the time of enrollment
NCT05633615,STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): ANC >= 1.0 x 10^3/uL and participants must not have received myeloid growth factor within 72 hours prior to this lab being drawn (within 14 days prior to step 3 crossover registration),1,STEP 3: CROSSOVER REGISTRATION (ARM 4 ONLY): ANC >= 1.0 x 10^3/uL and participants must not have received myeloid growth factor within 72 hours prior to this lab being drawn (within 14 days prior to step 3 crossover registration)
NCT05370547,Sexes Eligible for Study: All,0,Sexes Eligible for Study: All
NCT05243212,"At least 14 days must have elapsed since any prior systemic therapy at the time the subject starts the cyclophosphamide and fludarabine conditioning regimen, and subjects' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).",1,"At least 14 days must have elapsed since any prior systemic therapy at the time the subject starts the cyclophosphamide and fludarabine conditioning regimen, and subjects' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)."
NCT02456350,Patients of both genders must be willing to practice birth control for four months after receiving a lymphodepleting preconditioning regimen；,0,Patients of both genders must be willing to practice birth control for four months after receiving a lymphodepleting preconditioning regimen
NCT02915445,"Ages Eligible for Study: 18 Years to 65 Years   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)"
NCT03029273,Sign an informed consent before undertaking any trial-related activities;,0,Sign an informed consent before undertaking any trial-related activities
NCT04608487,"Ages Eligible for Study: 18 Years and older   (Adult, Older Adult)",0,"Ages Eligible for Study: 18 Years and older (Adult, Older Adult)"
NCT03265106,Male and female subjects with CD19+ B cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled.,1,Male and female subjects with CD19+ B cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled.
NCT05473221,Accepts Healthy Volunteers: No,0,Accepts Healthy Volunteers: No
NCT02822326,ALT/ AST 《 3x normal,1,ALT/ AST 《 3x normal
NCT04377932,"platelet count > 25,000/microliter (can be transfused)",0,"platelet count > 25,000/microliter (can be transfused)"
NCT04436029,High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).,0,High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).
NCT05191472,Have an Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%). Evaluation of ECOG is to be performed within 7 days prior to the start of study treatment.,0,Have an Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky > 60%). Evaluation of ECOG is to be performed within 7 days prior to the start of study treatment.
NCT04385173,Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspnea,1,Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspnea
NCT03142646,ECOG score ≤2,0,ECOG score ≤2
